Bellerophon Therapeutics Insider Sold Shares Worth $111,776, According to a Recent SEC Filing
Puissance Capital Management Lp, 10% Owner, on October 13, 2023, sold 1,076,841 shares in Bellerophon Therapeutics (BLPH) for $111,776. SEC Filing: https://www.sec.gov/Archives/edgar/data/1600132/0001
Bellerophon Therapeutics(BLPH.US) 10% Shareholder Sells US$111.78K in Common Stocks
$Bellerophon Therapeutics(BLPH.US)$ 10% Shareholder Puissance Capital Management LP sold 1.08 million shares of Common Stocks on Oct 13, 2023 at an average price of $0.1038 for a total value of $111.7
12 Health Care Stocks Moving In Friday's After-Market Session
GainersBellerophon Therapeutics (NASDAQ:BLPH) stock moved upwards by 17.1% to $0.12 during Friday's after-market session. Trading volume for this security closed at 2.1 million, accounting for 1394.7%
Dow Jumps Over 200 Points; JPMorgan Earnings Top Estimates
U.S. stocks traded mostly higher this morning, with the Dow Jones gaining more than 200 points on Friday. Following the market opening Friday, the Dow traded up 0.74% to 33,880.85 while the NASDAQ ros
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersBio-Path Hldgs (NASDAQ:BPTH) stock increased by 158.8% to $1.02 during Thursday's after-market session. Today's trading volume for this security ended up closing at 18.9 million shares, which i
Stocks That Hit 52-Week Lows On Tuesday
Tuesday saw 132 companies set new 52-week lows. Facts of Interest About Today's 52-Week Lows: Corning (NYSE:GLW) was the largest, in terms of market cap, to set a new 52-week low.Wheeler Real Estate
Stocks That Hit 52-Week Lows On Friday
 Friday's session saw 59 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Bristol-Myers Squibb (NYSE:BMY) was the largest firm by market cap to set a new 52-week low.Bi
Investors Parse Inflation Data as Wall Street Set to Open Higher in Friday Trading
US stocks look set to open Friday's trading session higher as investors eye key inflation data coming out today. According to the Bureau of Economic Analysis' monthly personal consumption expenditures
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersReata Pharmaceuticals (NASDAQ:RETA) shares rose 52.2% to $165.24 during Friday's pre-market session. The market value of their outstanding shares is at $6.2 billion. Bluejay Diagnostics (NASDAQ
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersLixte Biotech Hldgs (NASDAQ:LIXT) stock increased by 13.5% to $4.45 during Wednesday's after-market session. The market value of their outstanding shares is at $8.2 million. Align Tech (NASDAQ:
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersBullfrog AI Hldgs (NASDAQ:BFRG) shares moved upwards by 33.8% to $4.63 during Tuesday's regular session. Trading volume for Bullfrog AI Hldgs's stock is 42.6 million as of 13:30 EST. This is 84
What's Happening With Bellerophon Therapeutics Stock Today?
Bellerophon Therapeutics (NASDAQ:BLPH) stock is driving after receiving a delisting notice. The Listing Qualifications Department for the Nasdaq Exchange has decided to delist shares of Bellerophon st
Bellerophon Therapeutics Would Be Delisted From NASDAQ At The Opening Of Business On July 28, 2023, Unless The Company Timely Requests A Hearing Before NASDAQ Hearings Panel To Address The Deficiencies And Present A Plan To Regain Compliance - 8K
Bellerophon Therapeutics Would Be Delisted From NASDAQ At The Opening Of Business On July 28, 2023, Unless The Company Timely Requests A Hearing Before NASDAQ Hearings Panel To Address The Deficiencie
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go
Bellerophon Therapeutics (BLPH) Stock Sinks As Market Gains: What You Should Know
On June 24, 2023, Bellerophon Therapeutics Approved Reduction-In-Force Of Substantially All Of Its Employees, Including Its Executive Officers - Filing
The determination to effect the workforce reduction was made in connection with the Company's decision to terminate its REBUILD Phase 3 clinical study of INOpulse for the treatment of fibrotic Interst
The Latest Analyst Ratings for Bellerophon Therapeutics
Bellerophon Therapeutics (NASDAQ:BLPH) has observed the following analyst ratings within the last quarter: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings40000Last 30D100001M Ag
We're Hopeful That Bellerophon Therapeutics (NASDAQ:BLPH) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares
Express News | Bellerophon Therapeutics Price Target Cut to $2.00/Share From $30.00 by HC Wainwright & Co.
Express News | Bellerophon Therapeutics Is Maintained at Buy by HC Wainwright & Co.
No Data